Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. (1st June 2020)

• Record Type: Journal Article
• Authors: Porter, Danielle P; Weidner, Jessica M; Gomba, Laura; Bannister, Roy; Blair, Christiana; Jordan, Robert; Wells, Jay; Wetzel, Kelly; Garza, Nicole; Van Tongeren, Sean; Donnelly, Ginger; Steffens, Jesse; Moreau, Alicia; Bearss, Jeremy; Lee, Eric; Bavari, Sina; Cihlar, Tomas; Warren, Travis K
• Is Part Of: Journal of infectious diseases. Volume 222:Number 11(2020)
• Page Start: 1894
• Page End: 1901
• Publication Date: 2020-06-01
• Subjects: Marburg virus -- filovirus -- GS-5734 -- nonhuman primate -- remdesivir; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa290
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Marburg virus (MARV) is a filovirus with documented human case-fatality rates of up to 90%. Here, we evaluated the therapeutic efficacy of remdesivir (GS-5734) in nonhuman primates experimentally infected with MARV. Beginning 4 or 5 days post inoculation, cynomolgus macaques were treated once daily for 12 days with vehicle, 5 mg/kg remdesivir, or a 10-mg/kg loading dose followed by 5 mg/kg remdesivir. All vehicle-control animals died, whereas 83% of animals receiving a 10-mg/kg loading dose of remdesivir survived, as did 50% of animals receiving a 5-mg/kg remdesivir regimen. Remdesivir-treated animals exhibited improved clinical scores, lower plasma viral RNA, and improved markers of kidney function, liver function, and coagulopathy versus vehicle-control animals. The small molecule remdesivir showed therapeutic efficacy in this Marburg virus disease model with treatment initiation 5 days post inoculation, supporting further assessment of remdesivir for the treatment of Marburg virus disease in humans. Abstract : The small molecule remdesivir (GS-5734) showed therapeutic efficacy in a nonhuman primate model of Marburg disease with treatment initiation 5 days post inoculation, supporting further assessment of remdesivir for the treatment of Marburg virus disease in humans.